Navigation Links
China Biologic Products to Present at the SIG Beijing Management Summit
Date:9/8/2008

TAIAN CITY, Shandong, China, Sept. 8 /Xinhua-PRNewswire-FirstCall/ -- China Biologic Products, Inc. (OTC Bulletin Board: CBPO) ("China Biologic" or the "Company"), one of the leading plasma-based pharmaceutical companies in the People's Republic of China ("PRC"), today announced that the Company will present at the upcoming SIG Second Annual Beijing Management Summit held September 10 - 12, 2008 at the Grand Hyatt Beijing Hotel in Beijing.

The SIG Second Annual Beijing Management Summit is a two-and-a-half-day conference that brings together executives from public and private companies based in China and other emerging Asian economies. The event will showcase leading companies in the Chinese consumer, health care, Internet, and technology sectors, as well as companies in the global business services sector. Details of China Biologic's presentation follow.

Date: Thursday, September 11, 2008

Time: 3:20 p.m. Beijing time

Venue: The Grand Hyatt Beijing

1 East Chang An Avenue

Beijing, 100738

During the conference, the Company will be available to meet with analysts and portfolio managers. Participation in the SIG Second Annual Beijing Management Summit is by invitation only. Further information can be found at http://www.sig.com .

About China Biologic Products, Inc.

Through its indirect majority-owned subsidiary Shandong Taibang Biological Products Co. Ltd., China Biologic Products, Inc. (the "Company"), is principally engaged in the research, development, production and manufacturing and sale of plasma-based biopharmaceutical products to hospitals and other health care facilities in China. The Company's human albumin products are mainly used to increase blood volume and its immunoglobulin products are used for the treatment and prevention of diseases.

Safe Harbor Statement

This release may contain certain "forward-looking statements" relating to the business of China Biologic Products, Inc. and its subsidiary companies. All statements, other than statements of historical fact included herein are "forward-looking statements," including statements regarding: the impact of the maintenance on the Company's third quarter revenues; the ability of the Company to achieve its commercial objectives; the business strategy, plans and objectives of the Company and its subsidiaries; and any other statements of non-historical information. These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions, involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on its website ( http://www.sec.gov ). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.

Company Contact:

Mr. Y. Tristan Kuo

CFO

China Biologic Products, Inc.

Tel: +86-538-620-2206

Email: IR@chinabiologic.com

Web: http://www.chinabiologic.com

Investor Relations Contact:

Mr. Crocker Coulson

President

CCG Investor Relations

Tel: +1-646-213-1915 (NY office)

Email: crocker.coulson@ccgir.com

Web: http:///www.ccgir.com


'/>"/>
SOURCE China Biologic Products, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. China Biologics Production Facility Renews GMP Certification
2. China Bio Energy Holdings Group Announces Participation in the Susquehanna Second Annual Beijing Management Summit
3. Plexus Announces Expansion in Hangzhou, China
4. China Sky One Medical, Inc. Approved to List on the NASDAQ Global Market
5. China Pharma Holdings, Inc. Will Attend the Susquehanna Financial Group, LLP (SIG) Beijing Management Summit
6. ORBIS and Alcon Train Chinas Next Generation of Sight-Savers
7. China-Biotics, Inc. Continues to Broaden Bulk Additives Client Base
8. MicuRx Pharmaceuticals Selects Next-Generation Antibiotic Candidate Targeting MRSA and Expands Operation in China
9. China Kangtai Cactus Biotech Announces Record Second Quarter Results
10. China Biologic Products Reports Second Quarter 2008 Results
11. China-Biotics, Inc. Reports First Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2017)... ... 19, 2017 , ... The latest generation of the AutoBlock, ... prep for metals digestion—the addition of acids and reagents. The accessory fits any ... is ideal for any laboratory performing their own unique metals digestion method. ...
(Date:9/19/2017)... ... ... CEO and founder, Dr. Bob Harman DVM, MPVM, is featured in an interview with Dr. ... Dr. Harman and Dr. Riordan met in 2003 and have remained in contact over ... cell therapy and a fast friendship was formed. , Dr. Harman has been a leader ...
(Date:9/19/2017)... 2017 ValGenesis Inc., the global leader in ... announce the strategic partnership with VTI Life Sciences (VTI). ... services using the latest technology available in the ValGenesis ... with efficient and cost-effective validation services using ValGenesis VLMS. ... ValGenesis VLMS system. ...
(Date:9/19/2017)... ... September 19, 2017 , ... ... (NYS DFS) cybersecurity regulations have transitioned into full force and effect. The ... the state (“Covered Entities”) to conduct an annual, professional, comprehensive cybersecurity risk ...
Breaking Biology Technology:
(Date:4/5/2017)... KEY FINDINGS The global market ... CAGR of 25.76% during the forecast period of 2017-2025. ... for the growth of the stem cell market. ... MARKET INSIGHTS The global stem cell market is segmented ... The stem cell market of the product is segmented ...
(Date:3/30/2017)... 30, 2017 The research team of The ... (3D) fingerprint identification by adopting ground breaking 3D fingerprint minutiae recovery ... of speed and accuracy for use in identification, crime investigation, immigration ... ... A research team ...
(Date:3/27/2017)... 27, 2017  Catholic Health Services (CHS) has ... Society (HIMSS) Analytics for achieving Stage 6 on ... . In addition, CHS previously earned a place ... an electronic medical record (EMR). "HIMSS ... of EMR usage in an outpatient setting.  This ...
Breaking Biology News(10 mins):